Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 40 Pages - SKU: GMD6776024
|
|
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2012', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections. 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Vancomycin-Resistant Enterococcus Faecium Infections.
- A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Vancomycin-Resistant Enterococcus Faecium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Vancomycin-Resistant Enterococcus Faecium Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics under Development by Companies
- Late Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Products under Development by Companies
- Companies Involved in Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics Development
- Achillion Pharmaceuticals, Inc.
- Paratek Pharmaceuticals, Inc.
- Lorus Therapeutics Inc
- Oragenics, Inc.
- Piramal Life Sciences Limited
- MerLion Pharmaceuticals Pte Ltd
- Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ACH-702 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LOR-220 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Omadacycline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MU1140 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lipopetide Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PM181104 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lipopeptide Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SLP0905 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SLP0904 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Drug Profile Updates
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Dormant Products
- Vancomycin-Resistant Enterococcus Faecium Infections - Product Development Milestones
- Featured News & Press Releases
- Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H1 2012
- Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Achillion Pharmaceuticals, Inc., H1 2012
- Paratek Pharmaceuticals, Inc., H1 2012
- Lorus Therapeutics Inc, H1 2012
- Oragenics, Inc., H1 2012
- Piramal Life Sciences Limited, H1 2012
- MerLion Pharmaceuticals Pte Ltd, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Drug Profile Updates
- Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H1 2012
- Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Late Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Infectious Diseases Reports- Global Infectious Disease Treatment Market 2011-2014
- World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
- Global Infectious Disease Market Outlook: Facilities, Test Volume, and Sales Forecasts by Country
- Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
- Smallpox Global Clinical Trials Review, H2, 2011
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
